ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Amylyx Pharma plans to file ALS therapy with the EMA this year
April 16, 2021Amylyx Pharmaceuticals has announced its intention to submit a marketing authorisation application for its investigational amyotrophic lateral sclerosis (ALS) therapy AMX0035 to the European Medicines Agency (EMA) by the end of 2021. -
Amylyx announces FDA granted orphan drug designation for AMX0035 to treat Wolfram syndrome
November 19, 2020Amylyx Pharmaceuticals announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to AMX0035 for the treatment of Wolfram syndrome. -
Amylyx Pharmaceuticals announces AMX0035 demonstrated statistically significant treatment benefit in ALS in CENTAUR trial
December 20, 2019Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases ...
Pharma Sources Insight January 2025
